- Home
- ZTEK vs TCRX Comparison
ZTEK vs TCRX Comparison
Compare ZTEK & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | TCRX |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 67.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | TCRX |
|---|---|---|
| Price | $0.57 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 138.8K | ★ 869.2K |
| Earning Date | 02-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.37 | $0.73 |
| 52 Week High | $1.24 | $2.57 |
Technical Indicators
Market Signals| Indicator | ZTEK | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 33.79 |
| Support Level | $0.55 | N/A |
| Resistance Level | $0.56 | $1.28 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 67.02 | 2.61 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is engaged in developing opportunities in the graphene and related nano-materials industry based on its intellectual property, patents, and Albany graphite. The Company's operating segments are Intellectual Property Development, Biotech, and Albany Project. Intellectual Property Development includes the manufacturing and distribution of graphene-related products. Biotech includes service revenue generated through aptamer technology. The Albany Project includes the exploration and evaluation of assets and mineral exploration activities.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.